canyon landscape

An 18-month, open-label, multi-center phase IV study to assess the effect of ofatumumab 20mg SC monthly in treatment naïve, very early relapsing remitting multiple sclerosis.


The purpose of this study is to complement the ofatumumab clinical development pivotal trials by demonstrating clinical and MRI efficacy (both conventional and non-conventional) in a young adult, treatment naïve, very early MS patient population; patients earlier in the MS disease continuum than those in ASCLEPIOS I and II.

Open and enrolling subjects.
Phoenix, Arizona
Primary Sponsor
Novartis Pharmaceutical Corporation